Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xaluritamig plus abiraterone versus investigator's choice in chemotherapy-naive metastatic castration-resistant prostate cancer
NL-OMON60850Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Dec 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of xaluritamig, abiraterone, docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Amgen. Primary endpoint: Overall survival. Started Dec 2025; status: recruiting.
02
Drugs
xaluritamigabirateronedocetaxelcabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON60850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60850.